Targets › HSP90AA1
4 programs from 4 companies in 4 trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. (UniProt, P07900)
Open in Phaseline: the race on HSP90AA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| QuantumLeap Healthcare Collaborative | Ganetespib Heat shock protein HSP90 inhibitor | HSP90AA1, HSP90AB1 | Phase 2 | Breast Neoplasms | Dec 2030 |
| Taiho Pharmaceutical | Pimitespib HSP90 inhibitor | HSP90AA1, HSP90AB1 | Phase 1 | Gastrointestinal Stromal Tumors | Dec 2026 |
| Second Affiliated Hospital of Guangzhou Medical University | DC cell Vaccine Heat shock protein gp96-pulsed dendritic cell vaccine | HSP90AA1 | Phase 1 | Solid Tumor, Adult | Dec 2030 |
| H. Lee Moffitt Cancer Center and Research Institute | XL888 HSP90 inhibitor | HSP90AB1, HSP90AA1 | Phase 1 | Melanoma | – |
Solid Tumor, Adult (1) Breast Neoplasms (1) Gastrointestinal Stromal Tumors (1) Melanoma (1)
small molecule (2), other (1), mixed (1)
Second Affiliated Hospital of Guangzhou Medical University (1) QuantumLeap Healthcare Collaborative (1) Taiho Pharmaceutical (1) H. Lee Moffitt Cancer Center and Research Institute (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.